Filing Flows › Zai Lab (ZLAB) › Q3 2026 › vs Q2 2026
Zai Lab (ZLAB) Q3 2026 vs Q2 2026 (quarter over quarter)
Zai Lab's revenue rose $1.9M (+2%) from $106M in Q2 2026 to $108M in Q3 2026. The biggest changes: OPTUNE −$4.4M (-36%); NUZYRA +$4.0M (+23%); KarXT +$1.5M (+265%).
Zai Lab, Q3 2026: revenue $108M (-7% year over year), operating margin -58.2%, net loss $46.1M, operating cash flow −$57.9M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| ZEJULA | $32.3M | $32.1M | $205K | +0.6% |
| VYVGART / VYVGART Hytrulo | $24.1M | $23.9M | $205K | +0.9% |
| NUZYRA | $21.1M | $17.1M | $4.0M | +23% |
| QINLOCK | $8.8M | $9.6M | −$761K | -8% |
| XACDURO | $8.4M | $8.0M | $464K | +6% |
| OPTUNE | $7.8M | $12.2M | −$4.4M | -36% |
| AUGTYRO | $2.8M | $2.2M | $609K | +28% |
| KarXT | $2.0M | $552K | $1.5M | +265% |
| Other revenues | $856K | $755K | $101K | +13% |
| Revenue | $108M | $106M | $1.9M | +2% |
| Other income, net | $15.0M | $24.6M | −$9.7M | -39% |
| Income tax benefit | $1.9M | $1.0M | $850K | +83% |
| Net loss | $46.1M | $50.8M | −$4.7M | -9% |
| Costs & expenses | $171M | $183M | −$11.6M | -6% |
| Operating costs | $171M | $183M | −$11.6M | -6% |
| Cost of revenue | $51.3M | $48.2M | $3.1M | +7% |
| Research & development | $49.8M | $61.8M | −$12.0M | -19% |
| SG&A | $70.1M | $72.9M | −$2.8M | -4% |
| Operating cash sources | $73.3M | $79.5M | −$6.2M | -8% |
| Depreciation & amortization | $4.4M | $4.2M | $238K | +6% |
| Share-based compensation | $11.0M | $11.9M | −$942K | -8% |
| Cash used in operations | $57.9M | $63.4M | −$5.5M | -9% |
| Net loss absorbed | $46.1M | $50.8M | −$4.7M | -9% |
| Working capital & other | $27.1M | $28.7M | −$1.6M | -5% |
Questions
How much did Zai Lab's revenue grow quarter over quarter in Q3 2026?
Zai Lab's revenue rose $1.9M (+2%) from $106M in Q2 2026 to $108M in Q3 2026.
What drove Zai Lab's revenue change in Q3 2026?
OPTUNE −$4.4M (-36%); NUZYRA +$4.0M (+23%); KarXT +$1.5M (+265%).